Viridian Therapeutics (VRDN) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
16 Nov, 2026LUMVOA launch
First-quarter launch revenue was $24.7 million, with >100 patients on therapy as of Sept. 30; management said execution exceeded expectations.
Most patients had a proptosis response after one infusion; chronic TED patients showed complete diplopia resolution, and the planned course is five infusions vs. TEPEZZA’s eight.
Management expects a fast path to peak in a new-start market, but said the actual timeline remains to be seen; launch is still early.
Commercial access and execution
Formal policy coverage reached 30% of covered lives by the end of September; other patients can pursue access through medical exceptions.
Payers indicated parity pricing could support parity coverage; TEPEZZA reached 85% of covered lives in nearly five years, while management targets critical mass within 6–9 months of launch.
More than 95% of ~2,000 core prescribers had been engaged within four weeks of launch; the field team was active with physicians within 24 hours of launch.
A permanent J-code takes effect Jan. 1; management expects limited overall impact, with potential help for smaller infusion centers.
SubQ elegrobart
After two positive Phase III readouts earlier in 2026, the BLA for subQ IGF-1R is planned for Q1 2027.
Development plans include Q4-weekly and Q8-weekly regimens; the Q8-weekly course would involve three administrations at day 1, week 8 and week 16.
Management expects subQ convenience to expand the market, particularly by reaching patients deterred by infusions; IV is expected to remain an option for controlled settings and severe, sight-threatening disease.
Q4-weekly data showed diplopia response and resolution; Q8-weekly dosing may suit patients whose primary concerns are proptosis or pain.
Latest events from Viridian Therapeutics
- Lumvoa launch gains traction as TED and autoimmune pipeline milestones advance.VRDN
Corporate presentation - Phase I data support Q8W VRDN-008, with MG registrational development planned for mid-2027.VRDN
Study update - Lumvoa generated $24.7M in its first quarter as elegrobart advanced toward a Q1 2027 BLA.VRDN
Q3 2026 - Strong Lumvoa IV launch and pipeline progress position for TED market expansion and leadership.VRDN
Wells Fargo 21st Annual Healthcare Conference - FDA approval and strong cash reserves drive commercial and pipeline momentum in TED.VRDN
Q2 2026 - Advancing toward BLA filing with strong phase 3 data, breakthrough status, and launch readiness.VRDN
Goldman Sachs 46th Annual Global Healthcare Conference - Lumvoa and elegrobart drive innovation in TED, with a robust pipeline for autoimmune expansion.VRDN
Company presentation - FDA approves Lumvoa for all forms of TED, offering rapid, durable relief and immediate access.VRDN
FDA announcement - Significant efficacy and safety in chronic TED support a 2027 BLA for a subcutaneous autoinjector.VRDN
Study result